Expert evidence on tobacco taxation and prevention
Invited contribution to the FISC subcommittee debate on tobacco taxation, public-health incentives and fiscal policy.
Watch the hearing ↗POLICY IMPACT
Economics that enters the policy room.
My policy work focuses on translating evidence into clear choices on prevention, taxation, healthcare sustainability and public finance.
Research referenced in parliamentary debate
Evidence on prevention and healthcare savings has entered debate around the sustainability of the NHS and the Tobacco and Vapes Bill.
Expert engagement on nicotine and harm reduction
Contribution to expert discussion around nicotine products, evidence and public-health policy.
Parliamentary work on prevention and risk reduction
Member of the Parliamentary Technical-Scientific Intergroup on Prevention and Risk Reduction, contributing evidence on sustainable health expenditure and prevention.
FROM EVIDENCE TO POLICY
Four questions guide the policy work.
What is the measurable effect? Who bears the cost? How do incentives change behaviour? And can the policy remain credible when public finances are constrained?
Value before treatment
Prevention policy requires evidence on health gains, behavioural responses and the expenditure that may be avoided when risks are reduced earlier.
Incentives and unintended effects
Tax design can change behaviour as well as revenue. Economic analysis helps make those channels explicit and clarifies where public-health and fiscal objectives reinforce or conflict with each other.
Sustainability and productivity
Health systems face rising demand and tight budgets. Policy choices therefore need to consider productivity, prevention and the long-run path of public expenditure together.
Credibility under constraint
Policy recommendations are stronger when they recognise fiscal limits directly: who pays, over what horizon, and how the intervention changes incentives and public spending.